Wockhardt on Thursday said it has received zero observations from the US health regulator after inspection of its bioequivalence centre at Aurangabad in Maharashtra. The United States Food and Drug Administration carried out the inspection on June 10 and 12, it said. This outcome would lead to approvals of abbreviated new drug applications (ANDAs) in the pipeline for which bioequivalence studies are being or will be done in the centre, Wockhardt said.